Insilico Announces 30th AI-Driven Preclinical Candidate ISM0387 Targeting Glioblastoma

Bulletin Express08:04

Insilico Medicine Cayman TopCo (Insilico) disclosed that its UAE research team has advanced ISM0387, an MTA-cooperative PRMT5 inhibitor, to pre-clinical candidate status. The molecule was generated and optimized entirely through the company’s proprietary Pharma.AI platform.

The early discovery cycle—from molecular design to lead optimization—was completed in less than 12 months, with hit compounds identified in 30 days and lead optimization finalized within 6 months.

ISM0387 features an AI-designed novel structure, improved in-vitro activity and selectivity, high CNS penetration, and dose-dependent efficacy in disease models, positioning it as a potential therapy for glioblastoma.

This marks Insilico’s 30th AI-supported pre-clinical candidate to date. The nomination was acknowledged by the Emirates Drug Establishment, the Department of Health – Abu Dhabi, and the Abu Dhabi Investment Office.

The company reiterated that the announcement contains forward-looking statements subject to uncertainties and that the disclosed financial and operational data have not been audited or reviewed. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183745135?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183745135","market":"us","top_or_hot":-1,"title":"Insilico Announces 30th AI-Driven Preclinical Candidate ISM0387 Targeting Glioblastoma","media":"Bulletin Express","content":"<p>Insilico Medicine Cayman TopCo (Insilico) disclosed that its UAE research team has advanced ISM0387, an MTA-cooperative PRMT5 inhibitor, to pre-clinical candidate status. The molecule was generated and optimized entirely through the company’s proprietary Pharma.AI platform.</p>\n<p>The early discovery cycle—from molecular design to lead optimization—was completed in less than 12 months, with hit compounds identified in 30 days and lead optimization finalized within 6 months.</p>\n<p>ISM0387 features an AI-designed novel structure, improved in-vitro activity and selectivity, high CNS penetration, and dose-dependent efficacy in disease models, positioning it as a potential therapy for glioblastoma.</p>\n<p>This marks Insilico’s 30th AI-supported pre-clinical candidate to date. The nomination was acknowledged by the Emirates Drug Establishment, the Department of Health – Abu Dhabi, and the Abu Dhabi Investment Office.</p>\n<p>The company reiterated that the announcement contains forward-looking statements subject to uncertainties and that the disclosed financial and operational data have not been audited or reviewed. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Announces 30th AI-Driven Preclinical Candidate ISM0387 Targeting Glioblastoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Announces 30th AI-Driven Preclinical Candidate ISM0387 Targeting Glioblastoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine Cayman TopCo (Insilico) disclosed that its UAE research team has advanced ISM0387, an MTA-cooperative PRMT5 inhibitor, to pre-clinical candidate status. The molecule was generated and optimized entirely through the company’s proprietary Pharma.AI platform.</p>\n<p>The early discovery cycle—from molecular design to lead optimization—was completed in less than 12 months, with hit compounds identified in 30 days and lead optimization finalized within 6 months.</p>\n<p>ISM0387 features an AI-designed novel structure, improved in-vitro activity and selectivity, high CNS penetration, and dose-dependent efficacy in disease models, positioning it as a potential therapy for glioblastoma.</p>\n<p>This marks Insilico’s 30th AI-supported pre-clinical candidate to date. The nomination was acknowledged by the Emirates Drug Establishment, the Department of Health – Abu Dhabi, and the Abu Dhabi Investment Office.</p>\n<p>The company reiterated that the announcement contains forward-looking statements subject to uncertainties and that the disclosed financial and operational data have not been audited or reviewed. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1183745135","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183745135","pubTimestamp":1776989071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Insilico Medicine Cayman TopCo (Insilico) disclosed that its UAE research team has advanced ISM0387, an MTA-cooperative PRMT5 inhibitor, to pre-clinical candidate status. The molecule was generated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"Insilico宣布第30个人工智能驱动的针对胶质母细胞瘤的临床前候选药物ISM0387","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine Cayman TopCo (Insilico) disclosed that its UAE research team has advanced ISM0387, an MTA-cooperative PRMT5 inhibitor, to pre-clinical candidate status. The molecule was generated and optimized entirely through the company’s proprietary Pharma.AI platform.\nThe early discovery cycle—from molecular design to lead optimization—was completed in less than 12 months, with hit compounds identified in 30 days and lead optimization finalized within 6 months.\nISM0387 features an AI-designed novel structure, improved in-vitro activity and selectivity, high CNS penetration, and dose-dependent efficacy in disease models, positioning it as a potential therapy for glioblastoma.\nThis marks Insilico’s 30th AI-supported pre-clinical candidate to date. The nomination was acknowledged by the Emirates Drug Establishment, the Department of Health – Abu Dhabi, and the Abu Dhabi Investment Office.\nThe company reiterated that the announcement contains forward-looking statements subject to uncertainties and that the disclosed financial and operational data have not been audited or reviewed. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183745135","isCrawlerRequest":true}